Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Use of CYC202 (seliciclib) in Prior Trial Participants
2004-002510-11Phase 2Terminated
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Aug 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of seliciclib in non-small cell lung cancer (NSCLC), sponsored by Cyclacel Pharmaceuticals, Inc. Primary endpoint: Safety and tolerability. Started Aug 2005; status: terminated.
02
Drugs
seliciclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-002510-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002510-11.